Azacitidine Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 200 mg, 300 mg
Reference Brands: Onureg (USA)
Category:
Oncology Cancer Care
Azacitidine is used in the treatment of some kinds of blood cancer. It is used for the treatment of adult patients with all subtypes of Myelodysplastic Syndrome (MDS). It may be also used to treat other conditions, as determined by the doctor.
Azacitidine Tablet is available in Tablets
and strengths such as 200 mg, 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Azacitidine Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Azacitidine Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Azacitidine, marketed under the brand name Vidaza among others, is a chemotherapeutic agent used primarily in the treatment of myelodysplastic syndromes (MDS), myeloid leukemia, and juvenile myelomonocytic leukemia. As a chemical analog of cytidine, a nucleoside found in DNA and RNA, azacitidine integrates into nucleic acids and exerts its therapeutic effects by interfering with abnormal DNA methylation, ultimately promoting the reactivation of silenced genes that regulate normal cell growth and differentiation.
First synthesized in Czechoslovakia alongside its deoxy derivative, decitabine, azacitidine was developed as a potential cancer therapy. It received approval from the U.S. Food and Drug Administration (FDA) on May 19, 2004, for the treatment of myelodysplastic syndromes. Clinical studies have demonstrated its efficacy in normalizing blood cell counts and bone marrow morphology, with a significant proportion of patients experiencing reduced dependence on blood transfusions. Azacitidine represents a key therapeutic option for managing hematologic malignancies, offering improved hematologic function and quality of life for patients with MDS and related disorders.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing